Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Pacific Biosciences of California Debt-to-Equity?
Pacific Biosciences of CaliforniaPACB -2.51%53 Debt-to-Equity is 297.29 as of Mar. 2026, which is 24469% above its 10-year median of 1.21. GuruFocus rates PACB with a GF Score™ of 53/100 and a GF Value™ of $1.62 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 706 Medical Devices & Instruments companies, Pacific Biosciences of California ranks worse than 100% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Pacific Biosciences of California's Debt-to-Equity or its related term are showing as below:
PACB'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.11 Med: 1.21 Max: 297.29
Current: 297.29
During the past 13 years, the highest Debt-to-Equity Ratio of Pacific Biosciences of California was 297.29. The lowest was 0.11. And the median was 1.21.
PACB's Debt-to-Equity is ranked worse than 100% of 706
companies
in the Medical Devices & Instruments industry
Industry Median: 0.23
vs PACB: 297.29
Pacific Biosciences of California (NAS:PACB) Debt-to-Equity Explanation
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Pacific Biosciences of California Debt-to-Equity Related Terms
Pacific Biosciences of California Debt-to-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pacific Biosciences of California Debt-to-Equity Chart
For the Medical Devices subindustry, Pacific Biosciences of California's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pacific Biosciences of California Debt-to-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Pacific Biosciences of California's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Pacific Biosciences of California's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pacific Biosciences of California (PACB) has a Debt-to-Equity of 297.29 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Pacific Biosciences of California and its competitors. This is 24469% above median its historical median of 1.21. Over the past decade, Pacific Biosciences of California's Debt-to-Equity has ranged from 0.11 to 297.29. According to the industry distribution chart, Pacific Biosciences of California ranks #706 out of 706 companies in the Medical Devices & Instruments industry.
Is Pacific Biosciences of California's Debt-to-Equity too high?
Pacific Biosciences of California's current Debt-to-Equity of 297.29 is 24469% above median its 10-year median of 1.21. Over the past 10 years, this metric has ranged from a low of 0.11 to a high of 297.29. The Medical Devices & Instruments industry median Debt-to-Equity is 0.23. Pacific Biosciences of California's value of 297.29 is 129156.5% above this industry median. Based on the distribution chart, Pacific Biosciences of California ranks #706 out of 706 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Pacific Biosciences of California has a GF Score™ of 53/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Pacific Biosciences of California's Debt-to-Equity compare to KIDS and MOBI?
According to the Medical Devices & Instruments industry distribution chart, Pacific Biosciences of California ranks #706 out of 706 companies for Debt-to-Equity. This places Pacific Biosciences of California in the lower half of its industry. The industry median Debt-to-Equity is 0.23. Pacific Biosciences of California's value of 297.29 is 129156.5% above this benchmark. Historically, Pacific Biosciences of California's own Debt-to-Equity has ranged from 0.11 to 297.29 over the past decade. While the company's 10-year median is 1.21 vs. the industry median of 0.23, Pacific Biosciences of California has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Medical Devices & Instruments company?
The median Debt-to-Equity among Medical Devices & Instruments companies is 0.23, based on 706 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pacific Biosciences of California's current Debt-to-Equity of 297.29 is 129156.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Pacific Biosciences of California and its competitors. For the Medical Devices & Instruments industry, the median Debt-to-Equity is 0.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pacific Biosciences of California's current Debt-to-Equity is 297.29, which is 24469% above median its own 10-year median of 1.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pacific Biosciences of California stock overvalued right now?
Based on GuruFocus' analysis, Pacific Biosciences of California (PACB) is currently considered Modestly Undervalued. The stock's GF Value™ is $1.62, compared to a current price of $1.36 — trading 16% below its estimated fair value. The current Debt-to-Equity is 297.29, which is 24469% above median its 10-year median of 1.21 and 129156.5% above the Medical Devices & Instruments industry median of 0.23. Pacific Biosciences of California's overall GF Score™ is 53/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Pacific Biosciences of California (PACB), the current Debt-to-Equity is 297.29 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pacific Biosciences of California (PACB) Overvalued in 2026?
Based on GuruFocus' analysis, Pacific Biosciences of California stock appears to be undervalued.
The current stock price of $1.36 is trading 16% below its estimated GF Value™ of $1.62.
GuruFocus considers Pacific Biosciences of California to be Modestly Undervalued.
Key valuation signals for PACB:
Debt-to-Equity: 297.29 (24469% above median its 10-year median of 1.21)
GF Value™: $1.62 vs. price of $1.36 (16% below fair value)
Industry Position: 129156.5% above the Medical Devices & Instruments median (#706 of 706)
No single metric tells the full story. See the PACB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pacific Biosciences of California Business Description
Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Europe Middle East, and Africa and Asia-Pacific.
53GF Score
Get the complete analysis for PACB
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PACB has been successfully added to your 
